ONCASPAR (pegaspargase) is indicated as a component of multi-agent chemotherapeutic regimen for treatment of patients with:
• First-line acute lymphoblastic leukemia (ALL)
• ALL and hypersensitivity to native forms of L-asparaginase
All content on this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Shire and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.
This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on this site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of this site.
©2018 Shire US Inc., Lexington, MA 02421. All rights reserved. 1-800-828-2088.
SHIRE and the Shire logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.
ONCASPAR is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.
The most common adverse reactions with ONCASPAR (≥2%) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases.
Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) has been reported in patients exposed to ONCASPAR.
Please click here for Full Prescribing Information.